Which oral antidiabetic drug to combine with metformin to minimize the risk of hypoglycemia when initiating basal insulin?: A randomized controlled trial of a DPP4 inhibitor versus insulin secretagogues. (June 2016)

• Record Type: Journal Article
• Authors: Gautier, J.F.; Monguillon, P.; Verier-Mine, O.; Valensi, P.; Fiquet, B.; Dejager, S.; Charbonnel, B.
• Is Part Of: Diabetes research and clinical practice. Volume 116(2016)
• Page Start: 26
• Page End: 28
• Publication Date: 2016-06
• Subjects: DPP4 inhibitors -- Insulin secretagogues -- Clinical trial -- Basal insulin initiation -- Hypoglycemia; Diabetes -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462
• DOI: 10.1016/j.diabres.2016.04.008
• Languages: English
• ISSNs: 0168-8227

Abstract

Highlights: To explore which dual therapy should be maintained when initiating basal insulin in T2DM patients. A dual metformin/DPP4 inhibitor therapy allows achieving a similar efficacy vs. metformin/insulin secretagogues. However it limits the frequency of hypoglycemic episodes. Abstract: We conducted a pilot study to evaluate two therapeutic strategies at the time of insulin initiation in type 2 diabetic patients insufficiently controlled with metformin + insulin-secretagogues (IS, sulfonylureas or glinides). Patients were randomized to remain under the same dual therapy or to receive metformin + DPP4 inhibitors while starting insulin. Similar glycemic control was achieved in both groups. However less hypoglycemia was observed with DPP4 inhibitors despite higher doses of insulin.